论文部分内容阅读
目的探讨参麦注射液联合同步放化疗对于中晚期食管癌患者的治疗效果。方法中晚期食道癌患者88例,随机分为观察组与对照组,每组44例。对照组予以同步放化疗,观察组在对照组的基础上加用参麦注射液治疗,比较两组的疗效及不良反应。结果观察组的近期总有效率为81.8%,显著高于对照组的70.5%,差异有统计学意义(P<0.05);观察组的不良反应较对照组显著减轻,差异有统计学意义(P<0.05)。结论中晚期食管癌应用参麦注射液联合同步放化疗可提高临床疗效,降低放化疗不良反应,值得推广应用。
Objective To investigate the therapeutic effect of Shenmai injection combined with concurrent chemoradiotherapy on advanced esophageal cancer patients. Methods 88 cases of advanced esophageal cancer patients were randomly divided into observation group and control group, 44 cases in each group. The control group was given concurrent chemoradiotherapy. The observation group was treated with Shenmai injection on the basis of the control group. The curative effect and adverse reactions of the two groups were compared. Results The total effective rate in the observation group was 81.8%, which was significantly higher than that in the control group (70.5%) (P <0.05). The adverse reaction rate in the observation group was significantly lower than that in the control group (P <0.05). Conclusion The application of Shenmai injection combined with concurrent chemoradiotherapy in advanced esophageal cancer can improve the clinical curative effect and reduce the adverse reactions of radiotherapy and chemotherapy, which is worthy of popularization and application.